The trial was a randomized, double-blind, placebo-controlled study, the same basic design used in pharmaceutical research to separate a substance’s true effects from expectation or chance. Researchers enrolled 116 healthy adults who had never used kratom before, a detail that matters because it isolates the drug’s effects from any tolerance or expectation that regular users might bring to the experience. Participants were divided into cohorts and given either a single oral dose or 15 consecutive daily doses of Mitra-Leaf brand kratom capsules, made from dried leaf powder in amounts ranging from 500 to 4,000 milligrams, equivalent to roughly 6.65 to 53.2 milligrams of mitragynine, kratom’s primary active alkaloid. A separate group received a placebo. The study was conducted under International Conference on Harmonisation Good Clinical Practice guidelines, the same regulatory standard applied to drug trials generally, and its protocols were reviewed by an independent ethics committee and by Health Canada before any participant was enrolled.
To evaluate abuse-related outcomes, the researchers used two categories of standardized instruments. The first, the Drug Effects Questionnaire, is a validated tool that asks participants to rate subjective experiences such as feeling a drug’s effects, liking those effects, or wanting to take the drug again, all of which regulators consider relevant to a substance’s abuse liability. The second category addressed physical dependence and withdrawal, using the Subjective Opioid Withdrawal Scale and the Clinical Opiate Withdrawal Scale. Both instruments were originally developed to assess withdrawal in the context of opioid medications, and their use here reflects the fact that mitragynine acts as a partial agonist at the same opioid receptors targeted by conventional opioid drugs, even though kratom’s overall pharmacology differs from classical opioids in ways researchers are still working to fully characterize.
The results give a more textured picture than either “kratom is harmless” or “kratom is dangerous” framing typically allows. Subjective drug-effect scores did rise with dose, which is an expected pattern for any centrally active substance, but the increase was concentrated at the highest single dose tested and was not consistent across the middle dose levels. Notably, those subjective effects tended to decrease over the 15 days of repeated dosing rather than intensify, a pattern that runs counter to what researchers would expect if the product were producing escalating euphoria or reinforcing effects with continued use. On the withdrawal measures, the results were more clear-cut: no participant in any dose group met the threshold for clinically meaningful opioid withdrawal on either the COWS or SOWS scales, even after 15 consecutive days of dosing at the highest tested amount.
Adverse events did occur more frequently at higher doses, which is unsurprising and consistent with how most substances behave in dose-ranging studies. But the study’s authors characterized these events as generally mild, and importantly, no participant experienced a serious adverse event, and there were no deaths in the trial. Taken together, the authors concluded that oral administration of kratom at the doses tested was well tolerated, producing modest, dose-related subjective effects, minimal withdrawal symptoms, and a low rate of significant adverse events.
It is worth being precise about what this study does and does not establish. The product tested was a standardized dried leaf powder, Mitra-Leaf, administered in capsule form under controlled laboratory conditions with a known, consistent alkaloid content. That is meaningfully different from concentrated extracts or from products isolating or enhancing 7-hydroxymitragynine, a minor alkaloid found in trace amounts in natural leaf kratom but present at much higher concentrations in some manufactured products. Research on those concentrated forms has generally raised different and more serious concerns, and nothing in this trial should be read as evidence about the safety profile of those separate product categories. The study also involved kratom-naive adults over a maximum of 15 days, so it cannot speak to what happens with months or years of regular use, a pattern more representative of how many kratom consumers actually use the product.
This kind of standardized data has historically played an important role in how federal regulators evaluate substances for potential scheduling. An earlier assessment of kratom’s two most-discussed alkaloids, mitragynine and 7-hydroxymitragynine, conducted under the Controlled Substances Act’s eight-factor framework, previously concluded that mitragynine’s abuse potential fell within the range of many substances that remain uncontrolled, and that assessment specifically flagged the public health risks that could follow from removing access to natural kratom for people using it to avoid opioids. The new trial adds a rare piece of prospective, controlled human data to that ongoing body of evidence, rather than settling the broader debate on its own.
For readers trying to separate evidence-based understanding from marketing claims on one side and alarmist narratives on the other, the honest takeaway is a modest one. This single trial, using a specific standardized leaf-powder product, found limited signs of abuse-related reinforcement and minimal withdrawal over a short dosing period in people who had never used kratom before. It does not prove that kratom is safe for everyone, and it does not address the very different risk profile associated with concentrated or synthetic derivatives. What it does offer is one more careful, peer-reviewed data point in a research area that has long been shaped more by anecdote and political debate than by controlled clinical study, and its authors themselves framed the findings as support for further research into kratom’s safety profile and potential therapeutic uses, not as a final word.